Company: ABUS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001447028-25-000126
Chunk: 101

Company: Arbutus Biopharma Corp
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 2
Chunk 101
---
ual of lease-related operating expenses included in accounts payable and accrued liabilities. 

Other income (loss)

The components of our other income (loss) are summarized in the following table:

 Three Months Ended September 30,Nine Months Ended September 30, 2025202420252024(in thousands)Interest income$952 $1,747 $3,191 $5,121 Interest expense(23)(29)(79)(107)Foreign exchange (loss) gain(12)5 13 (16)Total other income$917 $1,723 $3,125 $4,998 

Interest income

The decrease in interest income for the three and nine months ended September 30, 2025 compared to the same periods in 2024 was due primarily to less interest earned on our cash and investment balances due to a lower average balance and a general decrease in market interest rates. 

Interest expense

Interest expense for the three and nine months ended September 30, 2025 and 2024 consisted primarily of non-cash amortization of discount and issuance costs related to the sale of a portion of our ONPATTRO royalty interest to OMERS in July 2019. The decrease is related to the declining balance of the unamortized discount and issuance costs. 

33

LIQUIDITY AND CAPITAL RESOURCES

The following table summarizes our cash flow activities for the periods indicated:

 Nine Months Ended September 30, 20252024(in thousands)Net loss$(29,745)$(57,388)Non-cash items6,609 5,453 Change in deferred license revenue(10,434)(880)Net change in other operating items(1,387)(1,720)Net cash used in operating activities(34,957)(54,535)Net cash provided by investing activities16,941 9,537 Issuance of common shares pursuant to the Open Market Sale Agreement— 44,124 Cash provided by other financing activities4,081 6,451 Net cash provided by financing activities4,081 50,575 Effect of foreign exchange rate changes on cash and cash equivalents13 (16)(Decrease) / Increase in cash and cash equivalents(13,922)5,561 Cash and cash equivalents, beginning of period36,330 26,285 Cash and cash equivalents, end of period$22,408 $31,846 

Since our incorporation, we have